Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development

Technical420 Site Search

Returned 44 result(s).

MAPS Canada Is Leading The Way For Psychedelic Use Cases In Modern Medicine

After the Multidisciplinary Association for Psychedelic Studies (MAPS) published promising results from a clinical trial using MDMA to treat post-traumatic stress disorder (PTSD), the psychedelic therapy sector has received extra attention.  According to The New York Times, MAPS could receive FDA approval by 2023 and we are favorable on the…

Will The ATAI Life Sciences IPO Bring Investor Interest Back To the Psychedelics Sector?

Although the psychedelic sector has come off its 2021 highs, we believe the sector is barely in the first inning of a major growth cycle.  Several psychedelic therapy companies are in advanced US Food and Drug Administration (FDA) clinical trials and we expect positive data from these studies to serve…

Pure Extracts Dual Vertical Approach Incorporating Cannabis and Psychedelic Compounds Is Starting To Pay Off

During the last month, Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) has reported several significant developments and is an opportunity that we are closely following. From forming strategic partnerships to purchasing cannabis biomass to launch a line of cannabis 2.0 products, Pure Extracts has been executing on…

MushroomStocks.com Deep Dive: Tryp Therapeutics (CSE:TRYP)

Over the past year there has been a significant increase in interest in companies that are focused on the psychedelic therapy market--a trend that we are following closely. Interest in these companies has been steadily rising in 2021, and we are focused on identifying businesses that have staying power. Tryp…

Field Trip Has A Warchest Of Cash To Propel R&D and M&A Moving Forward

If you have not been following Field Trip Health Ltd. (CSE: FTRP) (OTCQX: FTRPF), you may want to put the company on your radar after it closed a massive private placement. Last week, Field Trip reported to have closed a previously announced $95 million bought deal short form prospectus offering.…

Tryp Therapeutics Appoints Luke Hayes as Chief Financial Officer

Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce that it has appointed Luke Hayes as its Chief Financial Officer. Mr. Hayes has been active in the life science…

Tryp Therapeutics Has Been Laser Focused On Executing On Its Business Plan Post Listing

Last month, we highlighted Tryp Therapeutics Inc. (CSE: TRYP) as a hyper-focussed play on the psychedelic biotech market and an opportunity that our readers need to be aware of. So far this year, Tryp has been executing on previously announced growth initiatives and the story has made substantial advancements. TRYP…

Numinus Wellness Is Making Major Headway On Its MDMA Trials

Last week, Numinus Wellness Inc. (TSXV: NUMI) reported a major development and we want to issue an update on the opportunity following this announcement. The company is focused on creating an ecosystem of health solutions that are centered around the development of evidence-based psychedelic-assisted psychotherapies. Last week, Numinus announced that…

Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program

Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced that Albany Molecular Research ("AMRI") has begun the process of manufacturing the 200g non-GMP demonstration batch of psilocybin. This production step is one of…

Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor

Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has executed an advisory agreement with Dr. Joel Castellanos, a noted chronic pain physician at UC San Diego Medical Center to join…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link